
Lines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds-phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)-are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.


.png)


